...The Filipino Seafarer A Life between Sacrifice and Shopping by Gunnar M. Lamvik Dept. of Social Anthropology Norwegian University of Science and Technology Thesis submitted in partial fulfilment of the requirment for the Dr. Art. degree 2002 Contents Acknowledgements Part I Part II Introduction Migration – a Philippine specialty 2.1 Different perspectives on migration 2.2 The Filipinos – a people in motion 1 8 9 14 Part III Why do people go and who are actually leaving? 3.1 Inducements for migration 3.1.1 The “explorer” and the “escapist” 3.1.2 Migration seen as sacrifice 3.2 Preconditions for migration 3.2.1 Preconditions for migration on a structural level 3.2.2 Preconditions for migration at a family level 19 20 21 23 31 32 34 Part IV How they actually go – the broker 4.1 The patron and the compadre 4.2 The returned migrant 4.3 The private recruiter 4.4 The broker – some general and concluding remarks 38 40 43 45 52 Part V Life at sea 5.1 What characterizes a ship in the merchant marines? 5.2 The seafaring experience 5.2.1 The ship seen as a prison 5.2.2 The total institution 55 57 66 67 72 5.2.2.1 A total institution is a secluded place 75 5.2.2.2 A total institution follow a certain pace 77 5.2.2.3 Some running themes in the inmate culture 86 ii Part VI Cultural repercussions caused by the life at sea 6.1 The seafarer sees as a local, technical expert 6.2 The seafarer sees as a local cosmopolitan 100 101...
Words: 82194 - Pages: 329
...Twelfth Five Year Plan (2012–2017) Economic Sectors Volume II Copyright © Planning Commission (Government of India) 2013 All rights reserved. No part of this book may be reproduced or utilised in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage or retrieval system, without permission in writing from the publisher. First published in 2013 by SAGE Publications India Pvt Ltd B1/I-1 Mohan Cooperative Industrial Area Mathura Road, New Delhi 110 044, India www.sagepub.in SAGE Publications Inc 2455 Teller Road Thousand Oaks, California 91320, USA SAGE Publications Ltd 1 Oliver’s Yard, 55 City Road London EC1Y 1SP, United Kingdom SAGE Publications Asia-Pacific Pte Ltd 33 Pekin Street #02-01 Far East Square Singapore 048763 Published by Vivek Mehra for SAGE Publications India Pvt Ltd, Phototypeset in 11/13pt Minion Pro by RECTO Graphics, Delhi and printed at Saurabh Printers, New Delhi. Library of Congress Cataloging-in-Publication Data Available ISBN: 978-81-321-1131-3 (PB) The SAGE Team: Rudra Narayan, Archita Mandal, Rajib Chatterjee and Dally Verghese Twelfth Five Year Plan (2012–2017) Economic Sectors Volume II Planning Commission Government of India Thank you for choosing a SAGE product! If you have any comment, observation or feedback, I would like to personally hear from you. Please write to me at contactceo@sagepub.in —Vivek Mehra, Managing Director and CEO, SAGE Publications India Pvt...
Words: 131771 - Pages: 528
...CONTE N T S CHAI R M A N ’ S LETTE R DEAR SH AREH OL DERS FY2012 has been a good year for your Company. The key financial results were: ¥ Consolidated revenues increased by 30% to Rs. 96.7 billion in FY2012. ¥ Earnings before interest, taxes, depreciation and amortization (EBITDA)1 rose by 55% to Rs. 25.4 billion. ¥ Profit after Tax (PAT)2 grew by 45% to Rs. 15.3 billion. ¥ Diluted Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the biosimilars business continues along its impressive growth path. In my letter to you last year, I had discussed the critical importance of developing biosimilars in the years to come. I am happy to note that your Company’s global biosimilars business grew by 45% over last year and recorded sales of USD 26 million. Today, the biosimilars portfolio of Dr. Reddy’s constitutes (i) filgrastim, (ii) peg-filgrastim, (iii) rituximab and (iv) darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. These are helping to treat patients suffering from cancer — and at prices that...
Words: 128176 - Pages: 513